The two companies are coming together to work on a long term benefit project.
Qualcomm Life, one of Qualcomm, Inc.’s subsidiaries along with Novartis ADR have announced that both the companies are coming together to develop Novartis’ Breezhaler inhaler device. This device is made for patients who are suffering from chronic obstructive pulmonary disease – COPD. The latest device will allow the users to access the usage.
The Breezler consists of a device that allows the patient and phyisician to detect and report the usage of the product. It is basically integrated with the person’s smartphone and Novartis’ COPD mobile application. Through the mobile application that data will be transmitted to the pharmaceutical company’s COPD cloud.
With the help of this collected data, the physician will be able to monitor the patient’s condition and further prescribe the necessary treatment. It’s a very user friendly device which need to no assembling which is expected to launch in 2019, according to the announcement by the pharma organization. The COPD market is worth as much as $11.3 billion and by the year 2019 it is likely to touch $15.6 billion. With the compliance of the patients, many drug makers are working thoroughly to make drugs for this disease.
Currently the drugs that are being made for the specific purpose of the treatment of the disease are LABA/LAMA which is a one-day fixed dose consisting of QVA-149. Uneclidinium bromide/vilantero, along with olodaterol/tiotropium. The disease has two subtypes including emphysema and chronic bronchitis. According to research, back in 2011 over 10 million American citizens were suffering from chronic bronchitis out of which 70% were above the age of 45 and during the same time, over 4.7 million Americans had an emphysema attack; 90% of these citizens were above the age of 45.
In the year 2012, over 3 million people worldwide died of COPD; mostly people who suffer from the disease are from the low-income group. Presently, Novartis stock is being traded at $85.04 indicating a decrease of 1.36%. During the trade session, the stock reached a higher end of $85.26 and towards the lower end the stock was seen at $84.54. In the last 12 months, the highest at which the share price of seen at was $106.84 and the 52-week low was at $83.65. The market capitalization of the pharmaceutical company is $231.08 billion.
Currently 10% of the shares of the pharma organization is owned by institutional investors. The earnings per share reported by the health care organization was 3.44 with price to earnings ratio of 24.74.